Jiangsu Hengrui Medicine Co., Ltd.
600276
Rangering i aksjer
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Aksjekurs
$6.89
Markedsverdi
$43.94B
Endring (1 dag)
-2.91%
Endring (1 år)
-24.78%
Land
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)
Kategori
Healthcare
Inntekter for Jiangsu Hengrui Medicine Co., Ltd. (600276)
Inntekter i 2026 TTM: 0
Ifølge Jiangsu Hengrui Medicine Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Jiangsu Hengrui Medicine Co., Ltd. fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $1.24B | 26.71% |
| 2024 | $982.27M | 48.98% |
| 2023 | $659.33M | 14.60% |
| 2022 | $575.32M | -18.13% |
| 2021 | $702.70M | -33.43% |
| 2020 | $1.06B | 21.37% |
| 2019 | $869.67M | 32.96% |
| 2018 | $654.07M | 13.20% |
| 2017 | $577.79M | 33.13% |
| 2016 | $433.99M | 10.00% |
| 2015 | $394.53M | 35.79% |
| 2014 | $290.55M | 19.20% |
| 2013 | $243.75M | 12.88% |
| 2012 | $215.93M | 27.81% |
| 2011 | $168.94M | 29.63% |
| 2010 | $130.33M | 13.97% |
| 2009 | $114.35M | 66.01% |
| 2008 | $68.88M | -1.66% |
| 2007 | $70.05M | 89.01% |
| 2006 | $37.06M | 35.54% |
| 2005 | $27.34M | 31.05% |
| 2004 | $20.86M | 14.58% |
| 2003 | $18.21M | 36.38% |
| 2002 | $13.35M | 13.13% |
| 2001 | $11.80M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
